Purpura, Thrombocytopenic, Idiopathic
30
0
0
20
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.7%
2 terminated out of 30 trials
90.9%
+4.4% vs benchmark
37%
11 trials in Phase 3/4
40%
8 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (30)
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
The PROLONG Trial - Rituximab Maintenance Therapy in ITP
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)
Optimization of Glucocorticoid Taper Strategies for SLE-ITP
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects
The Study of Different Dose Rituximab in the Treatment of ITP
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Regulatory B Cells and Chronic Immune Thrombocytopenia
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia